Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) FCF Margin (2016 - 2025)

Fortress Biotech has reported FCF Margin over the past 12 years, most recently at 69.35% for Q4 2025.

  • Quarterly results put FCF Margin at 69.35% for Q4 2025, up 3326.0% from a year ago — trailing twelve months through Dec 2025 was 100.77% (up 4467.0% YoY), and the annual figure for FY2025 was 103.98%, up 4147.0%.
  • FCF Margin for Q4 2025 was 69.35% at Fortress Biotech, down from 34.65% in the prior quarter.
  • Over the last five years, FCF Margin for FBIO hit a ceiling of 34.65% in Q3 2025 and a floor of 18200.55% in Q2 2023.
  • Median FCF Margin over the past 5 years was 193.36% (2024), compared with a mean of 2535.09%.
  • Biggest five-year swings in FCF Margin: plummeted -1295569bps in 2022 and later surged 1804458bps in 2024.
  • Fortress Biotech's FCF Margin stood at 213.26% in 2021, then crashed by -6075bps to 13168.96% in 2022, then surged by 99bps to 87.17% in 2023, then dropped by -18bps to 102.61% in 2024, then soared by 32bps to 69.35% in 2025.
  • The last three reported values for FCF Margin were 69.35% (Q4 2025), 34.65% (Q3 2025), and 167.92% (Q2 2025) per Business Quant data.